Cellectis(US:CLLS)2026-03-20 13:02Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents, restricted cash, and fixed-term deposits amounted to $211 million, a decrease of $53 million from $264 million as of December 31, 2024, primarily due to cash payments and operational expenses [20][21] - The company reported a consolidated net loss attributable to shareholders for the twelve months ended December 31, 2025, with specific figures available in the press release [21] Business Line Data and Key Metrics Changes - The allogeneic CAR-T candidate lasme-cel achieved a 100% overall response rate in the target phase 2 population, converting all patients to transplant-eligible candidates [6][13] - The dual CAR-T candidate eti-cel demonstrated an 88% overall response rate and a 63% complete response rate in heavily pre-treated patients [9][16] Market Data and Key Metrics Changes - Cellectis is advancing its pivotal phase 2 trial for lasme-cel, with site openings in North America and Europe expected to continue into 2026 [8] - The company is also collaborating with partners like Servier and Allogene, with key milestones anticipated in 2026 [19] Company Strategy and Development Direction - Cellectis aims to transform into a late-stage development organization, focusing on delivering clinical results for patients with no therapeutic solutions [4][11] - The company is committed to internalizing its manufacturing capabilities, which has shown improved efficacy compared to external manufacturing [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial position to fund operations into the second half of 2027, allowing for continued development of lasme-cel and eti-cel [18] - The management highlighted the importance of their allogeneic CAR-T products in addressing unmet medical needs in oncology, particularly for patients with aggressive diseases [4][6] Other Important Information - The anticipated BLA submission for lasme-cel is planned for the second half of 2028, while eti-cel is expected to progress to pivotal phase 2 in 2027 with a BLA submission in H2 2029 [16] - The company is actively engaging in partnerships to enhance its gene editing platform and expand its product offerings [10][11] Q&A Session Summary Question: Update on lasme-cel and BALLI-01 enrollment - Management confirmed that recruitment is on track and expects to complete data analysis by the end of the year for the first 40 patients [24] Question: Expectations for dose optimization in the pivotal study - Management indicated that they anticipate being able to differentiate between the two dose levels of alemtuzumab based on efficacy and safety [25] Question: Details on Servier arbitration and its impact - The arbitration ruling allowed Cellectis to regain rights to UCART19, while remaining eligible for milestones related to cema-cel [30] Question: Importance of alemtuzumab in lymphodepletion - Management emphasized that alemtuzumab is critical for optimizing lymphodepletion and achieving better patient outcomes [33] Question: Update on esiCell and patient follow-up - Management provided a top-line update indicating strong complete remission rates and plans for further data sharing by the end of the year [37] Question: Application of lymphodepletion in outpatient settings - Management noted that regulatory requirements currently necessitate inpatient delivery, but there is potential for future outpatient use [58] Question: AstraZeneca partnership updates - Management expressed satisfaction with the collaboration but indicated that updates would be limited at AstraZeneca's request due to competitive considerations [60]